JP2022517442A - Caixに特異的な二環式ペプチドリガンド - Google Patents

Caixに特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022517442A
JP2022517442A JP2021563433A JP2021563433A JP2022517442A JP 2022517442 A JP2022517442 A JP 2022517442A JP 2021563433 A JP2021563433 A JP 2021563433A JP 2021563433 A JP2021563433 A JP 2021563433A JP 2022517442 A JP2022517442 A JP 2022517442A
Authority
JP
Japan
Prior art keywords
seq
referred
peptide ligand
sar
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563433A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020148526A5 (enExample
Inventor
バルダッサーレ レオナルド
シェン リューホン
ラニ ラシッド
ステイス キャサリン
トイフェル ダニエル
ウォーカー エドワード
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022517442A publication Critical patent/JP2022517442A/ja
Publication of JPWO2020148526A5 publication Critical patent/JPWO2020148526A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/01Hydro-lyases (4.2.1)
    • C12Y402/01001Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021563433A 2019-01-15 2020-01-15 Caixに特異的な二環式ペプチドリガンド Pending JP2022517442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1900526.3 2019-01-15
GBGB1900526.3A GB201900526D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for caix
PCT/GB2020/050070 WO2020148526A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for caix

Publications (2)

Publication Number Publication Date
JP2022517442A true JP2022517442A (ja) 2022-03-08
JPWO2020148526A5 JPWO2020148526A5 (enExample) 2023-01-25

Family

ID=65528170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563433A Pending JP2022517442A (ja) 2019-01-15 2020-01-15 Caixに特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220133732A1 (enExample)
EP (1) EP3911743A1 (enExample)
JP (1) JP2022517442A (enExample)
CN (1) CN113383074A (enExample)
GB (1) GB201900526D0 (enExample)
WO (1) WO2020148526A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
KR20240133798A (ko) 2021-12-17 2024-09-04 쓰리비 파마슈티컬스 게엠베하 탄산 무수화효소 ix 리간드
CN118852348A (zh) * 2022-02-11 2024-10-29 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
WO2024041532A1 (zh) * 2022-08-22 2024-02-29 赣州和美药业股份有限公司 含四价铂的配合物、前药及其制备方法和应用
CN120230182B (zh) * 2025-05-29 2025-08-22 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽及其核素标记物与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
GB201607827D0 (en) * 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Also Published As

Publication number Publication date
GB201900526D0 (en) 2019-03-06
US20220133732A1 (en) 2022-05-05
EP3911743A1 (en) 2021-11-24
CN113383074A (zh) 2021-09-10
WO2020148526A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP2022517442A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022518695A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022514255A (ja) Psmaに特異的な二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022514687A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022514618A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022518210A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP7460523B2 (ja) EphA2に特異的な二環ペプチドリガンド
JP6942147B2 (ja) Mt1−mmpに対して特異的な二環式ペプチド−毒素コンジュゲート
JP2022513223A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ox40に特異的な二環式ペプチドリガンド
JP2021506936A (ja) EphA2に特異的な二環ペプチドリガンド
CN114521197A (zh) 异串联双环肽复合物
JP2022512478A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022517040A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2022517399A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2020529427A (ja) Cd137に対して特異的な二環式ペプチドリガンド
JP2021514953A (ja) 多量体二環式ペプチドリガンド
CA3154672A1 (en) Bicyclic peptide ligand drug conjugates
JP2022544246A (ja) 修飾された多量体二環式ペプチドリガンド
JP2022513806A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022515720A (ja) Il-17に特異的な二環式ペプチドリガンド
JP2022515721A (ja) FAPαに特異的な二環式ペプチドリガンド
JP2024536391A (ja) 二環式ペプチドリガンド薬物コンジュゲート
JP2023506874A (ja) Il-17に特異的な二環式ペプチドリガンド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702